Apogee Therapeutics Inc. (APGE)

Profile

https://www.apogeetherapeutics.com

Apogee Therapeutics Inc. is a clinical-stage biotechnology company focused on developing biologic medicines for immunological and inflammatory diseases. Headquartered in Waltham, Massachusetts and founded in 2022, the company concentrates on validated immunology targets and applies advanced antibody engineering to optimize half-life, dosing convenience, and overall therapeutic profile. Its lead program, zumilokibart (formerly APG777), is a monoclonal antibody targeting IL-13, initially developed for atopic dermatitis and also being evaluated in asthma and eosinophilic esophagitis. Beyond this flagship candidate, Apogee is building a diversified pipeline of novel antibodies and combinations, such as APG273, directed at key inflammatory pathways relevant to dermatologic, respiratory, and gastroenterological conditions including asthma, chronic obstructive pulmonary disease, and other type 2 inflammatory disorders. Operating as a single reportable segment centered on research and development, Apogee collaborates with global clinical and manufacturing partners, aiming to bring differentiated biologic options to large, underserved inflammatory and immunology markets.